VaxcytePCVX
About: Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Employees: 414
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
87% more call options, than puts
Call options by funds: $48.1M | Put options by funds: $25.7M
62% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 86
1.79% more ownership
Funds ownership: 111.15% [Q3] → 112.94% (+1.79%) [Q4]
0% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 61
2% less funds holding
Funds holding: 324 [Q3] → 318 (-6) [Q4]
25% less capital invested
Capital invested by funds: $15.5B [Q3] → $11.5B (-$3.94B) [Q4]
48% less funds holding in top 10
Funds holding in top 10: 23 [Q3] → 12 (-11) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Needham Joseph Stringer 26% 1-year accuracy 29 / 113 met price target | 151%upside $90 | Buy Reiterated | 8 Apr 2025 |
Goldman Sachs Chris Shibutani 25% 1-year accuracy 3 / 12 met price target | 179%upside $100 | Buy Maintained | 1 Apr 2025 |
B of A Securities Jason Gerberry 26% 1-year accuracy 5 / 19 met price target | 282%upside $137 | Buy Maintained | 1 Apr 2025 |
Guggenheim Seamus Fernandez 43% 1-year accuracy 9 / 21 met price target | 346%upside $160 | Buy Reiterated | 12 Mar 2025 |
BTIG Thomas Shrader 11% 1-year accuracy 1 / 9 met price target | 346%upside $160 | Buy Reiterated | 24 Feb 2025 |
Financial journalist opinion









